With this expansion the company is seeking to secure supply in Canada and around the world for its Pentacel and Quadracel vaccine combinations, now licensed in 52 countries in Europe, Asia and the Americas.
Pentacel, a combination vaccine which protects children against five diseases - tetanus, diphtheria, polio, whooping cough and haemophilus influenzae type b - is the leading children's vaccine in Canada for these five major diseases, used in infants of 2,4,6 and 18 months, while the Quadracel combination is used in children at 4 to 6 years.
According to Sanofi Pasteur, these vaccines have been the cornerstone of Canada's infant immunisation programme, have had a dramatic impact on rates of whooping cough and all but eliminated Haemophilus Influenzae type b disease, while continuing to provide control of diphtheria, tetanus and polio.
Details of the expansion were not provided but it is understood that over 1,100 employees research, develop, manufacture and market vaccines to Canada and the world from the company's north Toronto site.
On site to celebrate the capital expansion was Ontario Premier and Minister of Research and Innovation Dalton McGuinty and Mark Lievonen, Sanofi Pasteur president.